Company Overview

Ovation Science Inc. is a Canada-based topical and transdermal drug delivery company focused on consumer health, medical cannabis, and pharmaceutical applications. The company develops and commercializes patented skin delivery technologies designed to improve the absorption, stability, and performance of active ingredients delivered through the skin. Ovation Science operates primarily within the health care, biotechnology, and topical therapeutics industries, with an emphasis on cannabinoid-based and non-cannabinoid topical products.

The company’s primary revenue drivers have included licensing agreements, commercialization partnerships, and product development activities tied to its proprietary topical delivery platform. Ovation Science is best known for its patented skin delivery technology marketed under the name Invisicare®, which is designed to enhance dermal penetration while maintaining cosmetic acceptability. The company has historically targeted medical cannabis producers, pharmaceutical developers, and consumer wellness brands seeking differentiated topical formulations. Ovation Science evolved from earlier topical formulation and drug delivery research efforts and expanded into cannabinoid-focused applications as legal cannabis markets developed in Canada and internationally.

Business Operations

Ovation Science conducts operations through research, intellectual property development, licensing activities, and commercial partnerships tied to topical and transdermal formulations. Its core business activities center on the commercialization of Invisicare®, including product formulation support, licensing of intellectual property, and collaborative development arrangements with third-party companies. The company has pursued applications spanning pain management, dermatology, antifungal products, and cannabinoid-infused topical products.

The company’s operations have primarily been based in Canada, although it has pursued international licensing and commercialization opportunities in multiple jurisdictions. Ovation Science has entered into agreements with cannabis and pharmaceutical-related companies seeking access to its delivery technology platform. Public disclosures indicate that the company’s strategic assets consist largely of intellectual property, formulation expertise, and proprietary topical delivery methodologies rather than large-scale manufacturing infrastructure. Data regarding certain commercial partnerships and revenue contributions has been limited in recent public disclosures, and some operational details are inconclusive based on available public sources.

Strategic Position & Investments

Ovation Science’s strategic direction has focused on expanding the commercial use of its topical and transdermal delivery technology across health and wellness sectors. The company has emphasized licensing and partnership-driven growth rather than vertically integrated manufacturing. Strategic initiatives have included pursuing applications for cannabinoid-based topicals, over-the-counter therapeutic products, and pharmaceutical collaborations intended to leverage enhanced skin absorption technologies.

The company has also sought to strengthen its intellectual property portfolio through patents and formulation research. Ovation Science has promoted the adaptability of Invisicare® across multiple therapeutic categories, positioning the platform as a differentiator in the competitive topical delivery market. Public filings and corporate disclosures have referenced efforts to enter additional geographic markets and commercial sectors, although the scale and financial impact of these initiatives have varied over time. Information regarding major acquisitions or large portfolio investments remains limited in publicly available filings.

Geographic Footprint

Ovation Science is headquartered in Canada, with corporate activities historically centered in British Columbia. The company’s commercial strategy has included pursuing licensing and partnership opportunities in North America and selected international markets where cannabinoid, pharmaceutical, or topical therapeutic products are permitted under local regulations.

The company’s operational footprint appears to be primarily partnership-driven rather than dependent on extensive owned international facilities. Ovation Science has indicated interest in expanding the use of its delivery technologies globally through collaborative agreements and commercialization arrangements. Public disclosures suggest market outreach efforts extending into regions with evolving cannabinoid and topical therapeutics markets, although the company’s largest operational concentration remains in Canada.

Leadership & Governance

Ovation Science has been led by executives with backgrounds in biotechnology, pharmaceuticals, commercialization, and public company management. Leadership communications have consistently emphasized intellectual property development, commercialization partnerships, and long-term value creation through differentiated topical delivery technologies. The company’s governance structure follows the framework typical of publicly traded Canadian issuers, with oversight provided through executive leadership and a board of directors.

Key executives and leadership figures identified in public company disclosures include:

• Terry Howlett – Chief Executive Officer
• Julia Frank – Chief Operating Officer
• John Thompson – Chief Financial Officer

Public filings indicate that management strategy has focused on leveraging proprietary technology platforms, expanding licensing opportunities, and pursuing commercialization relationships within regulated health and wellness industries. Certain executive roles and governance positions may change over time, and investors generally rely on the company’s most recent public filings for current leadership verification.